Keywords: American Diabetes Association meeting, Canagliflozine, Victoza, Dapagliflozin, Lanatus, Apidra, Taspoglutide, J&J, Novo Nordisk, Bristol-Myers Squibb, AstraZeneca, Sanofi-Aventis, Roche, Ipsen
Highlights of ADA meeting see good results for canagliflozin, Victoza, dapagliflozin, Lantus & Apidra and taspoglutide
Article | 28 June 2010
The 70th American Diabetes Association (ADA) meeting started over the weekend in Orlando, Florida, with a swathe of promising research ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
